Last reviewed · How we verify
NCT04496479
Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes
Phase 2 trial testing LYG-LIV0001 in End Stage Liver Disease in 12 participants. Currently enrolling.
20 August 2027
Quick facts
| Lead sponsor | LyGenesis, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 11 March 2022 |
| Primary completion | 20 August 2027 |
| Estimated completion | 30 December 2027 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- LYG-LIV0001 — full drug profile →
Conditions studied
- End Stage Liver Disease — all drugs for End Stage Liver Disease →
Sponsor
LyGenesis, Inc. — full company profile →
Who can join
Adults 18 to 70, any sex, with End Stage Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This Phase 2a clinical trial is a dose escalation study of the safety, tolerability, and efficacy of hepatocyte transplantation into lymph nodes via endoscopic ultrasound among subjects with end-stage liver disease.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Future medicine: from molecular pathways to the collective intelligence of the body.
Lagasse E, Levin M. · · 2023 · cited 31× · PMID 37481382 · DOI 10.1016/j.molmed.2023.06.007 -
Cell therapy for end-stage liver disease: Current state and clinical challenge.
Zhang L, Deng Y, Bai X, Wei X, et al · · 2024 · cited 5× · PMID 39602326 · DOI 10.1097/cm9.0000000000003332 -
Liver regeneration: unraveling the molecular mechanisms and clinical application.
Wang N, Guo M, Zhang C, Jiang R, et al · · 2025 · cited 1× · PMID 41420250 · DOI 10.1186/s12967-025-07412-3
Verify or expand the search:
- PubMed search for NCT04496479
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End Stage Liver Disease
Currently open trials in the same condition.
- NCT06173947 — SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury · recruiting
- NCT02581085 — Tocotrienol Against the Progression of End Stage Liver Disease · Phase 2 · active not recruiting
- NCT06418165 — Vienna Hypothermic Oxygenated Machine Perfusion Study · recruiting
- NCT03803423 — Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors · NA · recruiting
- NCT03228290 — Functional Assessment in Liver Transplantation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04496479 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LyGenesis, Inc.
- Last refreshed: 8 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04496479.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing